Phase II study of chemoradiotherapy using localized irradiation field for T1-3N0M0 esophageal carcinoma.

Phase II study of chemoradiotherapy using localized irradiation field for T1-3N0M0 esophageal carcinoma. - Phase II study of localized-field chemoradiotherapy for esophageal carcinoma.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004435

Enrollment

Registered

2010-10-25

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal carcinoma

Interventions

Chemoradiotherapy(CDDP+5FU+60Gy/30fr.)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - T1-3N0M0 untreated esophageal squamous cell carcinoma - Negative lymph node metastasis by PET - Performancestatus 0-1 - 20 - 75 years old - Sufficient liver and renal functions - Written informed consent is obtained

Exclusion criteria

Exclusion criteria: - Multiple or skip lesions - Prior thoracic irradiation or chemotherapy - Prior esophageal EMR - Synchronous malignancies - Uncontrolled severe complications - Possibility of pregnancy

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Recurrence-free survival, Incidence of adverse effects	—

Countries

Japan

Contacts

Public ContactKenji Nemoto

Yamagata University School of Medicine Department of Radiation Oncology

knemoto@med.id.yamagata-u.ac.jp+81-23-628-5386

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026